title: [Body-weight changes in psoriatic patients on systemic treatment].
authors.forename: M
authors.initials: M
authors.lastname: Forien
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: C
authors.initials: C
authors.lastname: Sin
authors.forename: A
authors.initials: A
authors.lastname: Marchal
authors.forename: M-L
authors.initials: ML
authors.lastname: Sigal
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001835:Body Weight / Q000187:drug effects*; D015897:Comorbidity; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab; D008134:Long-Term Care; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate